Biomea Fusion, Inc. – Trademark Portfolio
Entity Type: 03
Biomea Fusion, Inc. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 4 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 3 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include BIOMEA, BIOMEA FUSION, and WE AIM TO CURE. The owner is based in Redwood City, CA.
900 Middlefield Road, 4th Floor
Redwood City, CA 94063
Showing of trademarks Trademarks
Trademark Classifications
Biomea Fusion, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Biomea Fusion, Inc. have?
Biomea Fusion, Inc. has 7 U.S. trademarks filed with the USPTO. Of these, 6 registered, 1 abandoned.
What trademark classes does Biomea Fusion, Inc. file in?
Biomea Fusion, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Biomea Fusion, Inc.'s most well-known trademarks?
Biomea Fusion, Inc.'s registered trademark portfolio includes well-known marks such as BIOMEA, BIOMEA FUSION, and WE AIM TO CURE. These are among 6 currently registered trademarks in the portfolio.
What is Biomea Fusion, Inc.'s trademark registration success rate?
Biomea Fusion, Inc. has a 86% trademark registration rate, with 6 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.